Introduction {#sec1}
============

The development of disease-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offers promising alternatives to current *in vitro* and animal methods, particularly for the development of new treatments and the assessment of existing drugs for specific patient groups.[@bib1], [@bib2], [@bib3], [@bib4] However, interpretation of experiments is hampered by the high variability of hiPSC-CMs datasets, which could be attributed to many factors, including (1) substantial differences among patients (eg, control cells in Fatima et al[@bib2] vs Lahti et al[@bib5]); (2) immature phenotypes of hiPSC-CMs differentiated using *in vitro* techniques[@bib6]; and (3) varying culturing conditions used in different laboratories. Little is known about the ionic mechanisms underlying variability in hiPSC-CMs phenotypes and their response to pharmacologic action.

Long QT syndrome type 3 (LQT3) is the third most common form of long QT syndrome, caused by mutations in the SCN5A gene, which encodes for the Na^+^ channels. At the cellular level, the LQT3 characteristic mechanism is the gain of function of the Na^+^ channels, which transport fast and late Na^+^ currents (I~Na~ and I~NaL~, respectively). Such gain of function causes an Na^+^ inward leak during the action potential (AP), which prolongs its repolarization. Few therapies are currently available,[@bib7] which in general are based on drugs blocking the Na^+^ currents, with particular effect on I~NaL~, such as mexiletine[@bib8] and ranolazine.[@bib9] Beta-blockers, which proved to be effective on LQT1 and LQT2, are less effective on LQT3 and can lead to bradycardia.

This study aimed to investigate key factors determining variability of LQT3 hiPSC-CM phenotypes and their response to antiarrhythmic drugs, using populations of *in silico* hiPSC-CMs calibrated with experimental recordings for control and LQT3 hiPSC-CMs. Given its experimental characterization, we focus on the inherited form of LQT3 induced by the V1763M mutation,[@bib1] which causes enlarged I~NaL~ and consequently prolonged AP. We also evaluated the potential antiarrhythmic effects of mexiletine and ranolazine, two antiarrhythmic drugs with multichannel action and suggested efficacy in LQT3 treatment.[@bib7], [@bib10] Our approach provides an investigative platform toward precision medicine by extending *in vitro* studies to enable unraveling of the likely ionic mechanisms underlying variability in hiPSC-CM phenotypes for specific mutations and to evaluate their response to specific antiarrhythmic therapy.

Methods {#sec2}
=======

Control and LQT3 hiPSC-CM models {#sec2.1}
--------------------------------

The Paci2015 hiPSC-CM AP model was modified to include the I~NaL~ formulation for control and V1763M I~NaL~ mutation as explained in the [Supplementary Material (Sections S1.1, S1.2, and Table S1)](#appsec1){ref-type="sec"}.[@bib11], [@bib12] To investigate hiPSC-CM phenotypical variability under control conditions, a random population of hiPSC-CM control models was developed as proposed in Britton et al,[@bib13] calibrated using experimental data from Ma et al,[@bib14] Moretti et al,[@bib15] Ma et al,[@bib1] Fatima et al,[@bib2] Lahti et al,[@bib5] and Kujala et al[@bib16] as further explained in the [Supplementary Material (Sections S1.3 and S1.4, and Supplementary Table S2)](#appsec1){ref-type="sec"}. The LQT3 mutant population of hiPSC-CM models was then developed by incorporating the V1763M mutation I~NaL~ formulation in all models included in the control population (ie, no further calibration was performed on the mutant population, following an approach similar to that of Passini et al[@bib17]). Models in the mutant population were classified as asymptomatic and symptomatic as explained in [Section S1.5](#appsec1){ref-type="sec"} of the [Supplementary Material](#appsec1){ref-type="sec"}.

*In silico* drug tests {#sec2.2}
----------------------

Effects of mexiletine and ranolazine at 5, 10, and 20 μM doses were assessed *in silico* on the control and mutant populations considering their multichannel effects on I~Na~, I~NaL~, the rapid delayed rectifying potassium current (I~Kr~), and the L-type calcium current (I~CaL~) using the single pore block model, consistent with data from ion channel assays (see [Supplementary Material, Section S1.6](#appsec1){ref-type="sec"}, and [Supplementary Table S3](#appsec1){ref-type="sec"}). Examples of drug effects on the Na^+^ current are reported in [Supplementary Figures S1](#appsec1){ref-type="sec"} and [S2](#appsec1){ref-type="sec"}. To compare the effect of drug action on hiPSC vs adult cardiomyocytes, simulations were also conducted considering the same drug doses on 10 illustrative control and mutant models of human adult ventricular cardiomyocytes, based on the O'Hara-Rudy model[@bib18] (see [Supplementary Material, Section S1.6](#appsec1){ref-type="sec"}). Unless otherwise specified, results are reported as mean ± SD.

Results {#sec3}
=======

LQT3 mutation {#sec3.1}
-------------

The hiPSC-CMs APs and the simulated I~NaL~ of the baseline models for the control and mutant conditions are described in [Figures 1A](#fig1){ref-type="fig"} and [1B](#fig1){ref-type="fig"}, respectively, and in [Supplementary Table S4](#appsec1){ref-type="sec"}. [Figure 1C](#fig1){ref-type="fig"} shows the excellent match of simulations with experimental data by Ma et al,[@bib1] reproducing the mean AP prolongation of the LQT3 V1763M mutation: +43% in simulation vs +48% in the experiments (control 434 ± 108 ms vs mutant 645 ± 239 ms).Figure 1**A:** Comparison between Paci2015 hiPSC-CM model in control and LQT3 conditions. **B:** Simulated control and mutant Na^+^ currents (I~Na~ + I~NaL~). *Inset:* persistent I~NaL~ 200 ms after stimulus, for comparison with experimental data. *Red arrows* indicate simulated I~NaL~ values used for comparison with experimental data. **C:** Comparison between simulated and experimental[@bib1] persistent I~NaL~ The mutant I~NaL~ is 4.86 times larger than control current. **D:** APs generated by maximum conductance sampling. *Red* indicates rejected models; *cyan* indicates models included in the control population. Baseline AP from Paci2015 is represented in *black.***E:** Comparison between control *(cyan)* and mutant *(magenta)* populations. The mutant population features prolonged APs. The baseline Paci2015 model is represented in *black;* its mutant version in shown in *gray.* AP = action potential; hiPSC-CM = human induced pluripotent stem cell-derived cardiomyocyte; LQT3 = long QT syndrome type 3.

Control and LQT3 hiPSC-CMs populations {#sec3.2}
--------------------------------------

[Figure 1D](#fig1){ref-type="fig"} shows the APs of the random population (n = 10,000) and of the calibrated control population (n = 1,463). [Figure 1E](#fig1){ref-type="fig"} compares the APs of the control and mutant populations (n = 1,401). [Figure 2A](#fig2){ref-type="fig"} provides a quantitative description of the APs biomarkers obtained with both populations, clearly showing action potential duration (APD) prolongation (eg, ΔAPD~90~ = +34.3%) in the mutant population. [Supplementary Figure S3](#appsec1){ref-type="sec"} shows how biomarkers computed from the control population cover the experimental biomarker space.Figure 2**A:** Simulated AP biomarkers in control vs mutant hiPSC-CM populations, showing APD prolongation with the mutation. **B:** Experimental and simulated AP biomarkers in control and LQT3 hiPSC-CM. A subpopulation of 410 hiPSC-CM models was extracted from the control population by calibration only with the dataset of Ma et al.[@bib1] The 150 models in agreement with the experimental data reported by Ma et al[@bib1] were extracted from the mutant population. **C:** APs from control and mutant subpopulations for experiments (redrawn from Ma et al[@bib1] with permission from Elsevier) and six illustrative *in silico* APs (three control and three mutant). The simulated *solid line* APs represent baseline control and mutant models; *dashed* and *dashed-dotted* line APs represent two additional models from the populations in control and mutant conditions, respectively. The top left and top right panels of [Figure 2C](#fig2){ref-type="fig"} were adapted from Figure 4 from International Journal of Cardiology, Volume 168, Issue 6, Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NB, Tan TH, Wong KY, Shim W, Wong P, Cook SA, Liew R, Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells, Pages 5277-5286, Copyright (2013), with permission from Elsevier. Anyone wishing to reuse either the original or the adapted figure must require formal permission from Elsevier to do so.APA = AP amplitude; APD = AP duration; MDP = maximum diastolic potential; Peak = peak voltage; Rate = rate of spontaneous APs; V~Max~ = maximum upstroke velocity. Other abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Because the LQT3 V1763M mutation has been experimentally characterized in only one hiPSC-CM dataset,[@bib1] we also obtained a subpopulation of mutant models calibrated using only this dataset to assess the capability of the simulated population in reproducing the mutation experimental effects. [Figure 2B](#fig2){ref-type="fig"} shows the agreement in the effect of the mutation in simulations vs experimental data or all the biomarkers (top panels: rate of spontaneous APs (rate) and maximum upstroke velocity (V~Max~); bottom panels: APD). Finally, [Figure 2C](#fig2){ref-type="fig"} shows a comparison between illustrative experimental APs (top panels) from Ma et al[@bib1] and selected simulated APs (bottom panels).

Symptomatic vs asymptomatic mutant models {#sec3.3}
-----------------------------------------

The mutant population was split into asymptomatic (with the shortest APDs; n = 678) and symptomatic (n = 723) groups ([Figures 3A](#fig3){ref-type="fig"} and [3B](#fig3){ref-type="fig"}). The ionic bases of the phenotypic differences were investigated, highlighting important differences in maximal conductances for I~CaL~, I~Kr~, the inward rectifying potassium current (I~K1~), the calcium sarcolemmal pump (I~pCa~), and I~NaL~ ([Figure 3C](#fig3){ref-type="fig"}). In particular, symptomatic hiPSC-CMs models displayed larger I~NaL~ (median 78.3 vs 55.5 S/F, +41.0%), larger I~CaL~ (105 vs 83 cm^3^/F/s, +27.1%), smaller I~pCa~ (0.53 vs 0.58 A/F, --8.6%), and smaller I~Kr~ (41.8 vs 50.8 S/F, --17.7%). Larger I~CaL~ means larger inward current, whereas smaller I~Kr~ and I~pCa~, reduced outward current; these factors resulted in reduced repolarization reserve in mutant symptomatic models. Finally, larger I~K1~ in the symptomatic models (28.1 vs 24.8 S/F, +13.6%) induced greater activation of the Na^+^ currents (see [Supplementary Table S5](#appsec1){ref-type="sec"} and [Supplementary Figure S4](#appsec1){ref-type="sec"}). We finally evaluated whether the control models corresponding to symptomatic vs asymptomatic mutant models displayed differences in biomarkers. The analysis reveals differences in biomarkers between those two control hiPSC-CM groups as shown in [Supplementary Figure S5](#appsec1){ref-type="sec"}. Control models leading to symptomatic LQT3 models display decreased rate (--12%), increased V~Max~ (+27%), and prolonged APD~90~ (+34%) compared to those leading to asymptomatic LQT3 models after introduction of the I~NaL~ mutation.Figure 3Symptomatic *(black)* vs asymptomatic *(green)* APs **(A)** and biomarkers **(B)** from simulated hiPSC-CMs. **C:** Maximum conductances of symptomatic and asymptomatic models. I~CaL~ = L-type calcium current; I~f~ = hyperpolarization-activated cyclic nucleotide-gated funny current; I~K1~ = the inward rectifying potassium current; I~Kr~ = rapid delayed rectifying potassium currents; I~Ks~ = slow delayed rectifying potassium currents; I~Na~ = fast sodium current; I~NaK~ = sodium-potassium pump; I~NaL~ = late sodium current; I~NCX~ = sodium-calcium exchanger; I~pCa~ calcium sarcolemmal pump; I~to~ = transient outward potassium current. Other abbreviations as in [Figure 1](#fig1){ref-type="fig"} and [Figure 2](#fig2){ref-type="fig"}.

Drug tests {#sec3.4}
----------

### Mexiletine {#sec3.4.1}

[Figure 4](#fig4){ref-type="fig"} illustrates the effect of the three doses of mexiletine on the APD of control and mutant populations (further characterized in [Supplementary Table S6](#appsec1){ref-type="sec"}). Interestingly, because of the different effects of mexiletine on control and mutant Na^+^ currents,[@bib8] results show slight APD~90~ prolongation in controls (+5.1 ms at 10 μM and +23.5 ms at 20 μM), consistent with experiments by Malan et al[@bib4] on stimulated hiPSC-CMs, and significant AP shortening (--96.2 ms at 10 μM and --76.6 ms at 20 μM) in the mutant population ([Figures 4A](#fig4){ref-type="fig"} and [4B](#fig4){ref-type="fig"}). Due to I~Na~ block by mexiletine ([Supplementary Table S3](#appsec1){ref-type="sec"}), a dose-dependent amount of models stopped producing APs (216 at 5 μM, 483 at 10 μM, and 784 at 20 μM). The most significant differences between the mutant models producing or not producing APs at 20 μM are the smaller I~Na~ (median 5006 vs 3377 S/F, --33.3%) and the greater I~K1~ (25.6 vs 36.0 S/F, +40.6%) ([Figure 4D](#fig4){ref-type="fig"}, panels a and b).Figure 4**A:** ΔAPD~90~ for models of control and LQT3 hiPSC-CM populations at 5, 10, and 20 μM mexiletine doses. **B:** Mexiletine effects on AP biomarkers of mutant hiPSC-CM populations. **C:** Mexiletine effects on AP biomarkers of symptomatic and asymptomatic mutant hiPSC-CM models. **D:** Ionic properties underlying phenotypic differences in hiPSC-CM after administration of 20 μM mexiletine. The mutant models producing APs (panels a and b) are then split in panels c--f according to their ΔAPD. I~Na~ is smaller (a) (median 4,331 vs 5,846 S/F, --26%) and I~K1~ is larger (b) (31.5 vs 20.8 S/F, +51%) in models not producing an AP than in those with AP with mexiletine. Models with APD prolongation after mexiletine application have a very weak I~K1~ (d) (16.9 vs 22.1 S/F, --23%), smaller I~NaL~ (e) (44.9 vs 77.2 S/F, --42%), and larger I~CaL~ (f) (101 vs 84 cm^3^/F/s, +21%), with small difference in I~Na~ (c) (5,487 vs 5,927 S/F, --7%). Abbreviations as in [Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

[Figure 4C](#fig4){ref-type="fig"} shows the effect of 20 μM of mexiletine on the asymptomatic and symptomatic models from the mutant population. The global effect is APD shortening; APD~90~ was shortened by 111.4 ms (--18.7%) for the symptomatic models and by 33.5 ms (--8.1%) for the asymptomatic models. [Figure 4A](#fig4){ref-type="fig"} and [Supplementary Table S6](#appsec1){ref-type="sec"} show that a large number of mutant models exhibited APD prolongation when administered a high dose (20 μM) of mexiletine. By comparing the subgroups of models that showed a prolongation or shortening of APD~90~ in response to 20 μM mexiletine (see [Supplementary Figure S6](#appsec1){ref-type="sec"}), we noted depolarized maximum diastolic potential (MDP) and reduced V~Max~ in the subgroup with positive ΔAPD~90~, which was confirmed by reduced I~K1~ ([Figure 4D](#fig4){ref-type="fig"}, panel d, and [Supplementary Figure S6](#appsec1){ref-type="sec"}, inset), revealing decreased Na^+^ current availability in these cells (illustrative APs in [Supplementary Figure S7](#appsec1){ref-type="sec"}). Under these conditions, strong block of I~Na~ (as for mexiletine) has a dramatic effect on AP upstroke, delaying it and prolonging APD ([Figure 4D](#fig4){ref-type="fig"}, panels c and d). Moreover, during the repolarization phase, the same group showed smaller I~NaL~, that is, the main mexiletine target (--42%), and greater I~CaL~ (+21%) ([Figure 4D](#fig4){ref-type="fig"}, panels e and f).

As shown in [Section S2.1](#appsec1){ref-type="sec"} of the Supplementary Material [(see Supplementary Figures S8 and S9](#appsec1){ref-type="sec"}, and [Supplementary Tables S7--S9](#appsec1){ref-type="sec"}), mexiletine had similar effects on AP shape in simulations with the 10 adult cardiomyocytes models based on the O\'Hara-Rudy model (mean ΔAPD~90~ +13% for control and --8% for mutant models). Consistent with the hiPSC-CM simulations, mexiletine exhibited stronger action on symptomatic adult mutant models (mean ΔAPD~90~ = --24%) than in asymptomatic models, in which AP was prolonged (mean ΔAPD~90~ = +7%). This shows that the paradoxical prolongation of APD~90~ occurs mostly in models characterized by reduced I~NaL~ (as in the asymptomatic models).

Ranolazine {#sec3.5}
----------

[Figure 5A](#fig5){ref-type="fig"} shows how ranolazine dragged the APD values of mutant models toward control values. As shown in [Figure 5B](#fig5){ref-type="fig"}, APD~90~ in the control and mutant populations was shortened on average --9.6 ms and --57.1 ms at 10 μM, --16.0 ms and --74.1 ms at 20 μM, respectively, and to a greater extent in the mutant group (see [Supplementary Table S6](#appsec1){ref-type="sec"}). Again, models characterized by large I~K1~ and small I~Na~ stopped producing APs (3 at 5 μM, 12 at 10 μM, and 53 at 20 μM). At 20 μM, the group not producing APs showed greater I~K1~ (+51.35%) and smaller I~Na~ (--25.78%) compared to the group producing APs ([Figure 5D](#fig5){ref-type="fig"}, panels a and b). As for mexiletine, in the control population a large number of models exhibited APD~90~ prolongation (see [Supplementary Table S6](#appsec1){ref-type="sec"}). This phenomenon also affected a limited number of mutant models (11 at 5 μM, 23 at 10 μM, and 83 at 20 μM ranolazine) and to a lesser extent compared to mexiletine. Again, these models show smaller V~Max~ and depolarized MDP as consequence of reduced I~K1~ ([Figure 5D](#fig5){ref-type="fig"}, panel d), which affects Na^+^ current availability, thus delaying the upstroke in case of I~Na~ block. Furthermore, these models show smaller I~NaL~ (--42% at 20 μM) compared to the models exhibiting AP shortening ([Figure 5D](#fig5){ref-type="fig"}, panel e). For the same dose, ranolazine blocks I~Na~ to a lesser extent than mexiletine, therefore leading to APD~90~ prolongation in fewer (83) models. Finally, [Figure 5C](#fig5){ref-type="fig"} shows how 20 μM ranolazine affects the symptomatic and asymptomatic models. The global effect is APD shortening, by 96.5 ms (--16.2%) for the symptomatic models and by 51.23 ms (--12.4%) for the asymptomatic models.Figure 5**A:** ΔAPD~90~ for models of control and LQT3 hiPSC-CM populations at 5, 10, and 20 μM ranolazine doses. **B:** Ranolazine effects on AP biomarkers of mutant hiPSC-CM populations. **C:** Ranolazine effects on AP biomarkers of symptomatic and asymptomatic mutant hiPSC-CM models. **D:** Ionic properties underlying phenotypic differences in hiPSC-CM after administration of 20 μM ranolazine. The mutant models producing APs (panels a and b) are then split in panels c--f. I~Na~ is smaller (a) (median 3,384 vs 5,049 S/F, --33%) and I~K1~ larger (b) (36.1 vs 25.9 S/F, +41%) in models not producing an AP than in those with AP with ranolazine. Models with APD prolongation after ranolazine application have a very weak I~K1~ (d) (16.8 vs 26.4 S/F, --37%) and smaller I~NaL~ (e) (41.3 vs 70.8 S/F, --41%) with small differences in I~Na~ (c) (5,286 vs 5,037 S/F, +5%) and I~CaL~ (f) (101 vs 91 cm^3^/F/s, +11%). Abbreviations as in [Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

As for mexiletine, also in the human adult APs models, ranolazine showed stronger action on the five symptomatic mutant models (mean ΔAPD~90~ = --12%) than on the five asymptomatic ones (mean ΔAPD~90~ = +8%) (see [Supplementary Section S2.1](#appsec1){ref-type="sec"}, [Supplementary Figures S8 and S9](#appsec1){ref-type="sec"}, and [Supplementary Tables S7--S9](#appsec1){ref-type="sec"}).

Finally, in [Section S2.2](#appsec1){ref-type="sec"} of the [Supplementary Material](#appsec1){ref-type="sec"}, we also report the effect of 100 μM ranolazine (see [Supplementary Figure S10](#appsec1){ref-type="sec"} and [Supplementary Table S10](#appsec1){ref-type="sec"}), which is able to restore the mutant symptomatic APD to its asymptomatic value (422 vs 414 ms).

Discussion {#sec4}
==========

The present study demonstrates the ability of populations of hiPSC-CMs *in silico* models to simulate and suggest potential mechanisms, which can be further tested in laboratory, underlying experimental variability in AP of control and LQT3 mutant cells observed *in vitro*, as well as their response to two antiarrhythmic blockers used in the treatment of LQT3 syndrome. Additional specific findings include the following: (1) the key properties determining symptomatic vs asymptomatic LQT3 hiPSC-CM phenotypes in the simulations are the magnitude of I~NaL~, in combination with I~CaL~, I~Kr~ and I~K1~, which, depending on their magnitudes, either exacerbate or compensate the mutation effects; (2) variability of mutant hiPSC-CM responses to antiarrhythmic drugs can be reproduced *in silico*, enabling the investigation of likely underlying ionic mechanisms; (3) mexiletine confirmed its efficacy in shortening APD, but in subpopulations it led to termination of the trigger of spontaneous APs or to paradoxical APD prolongation due to slowing of depolarization and reduced weak repolarization, in models with reduced I~NaL~ and large I~CaL~; and (4) ranolazine proved to be as effective as mexiletine in shortening APD and led to AP termination and paradoxical APD prolongation in fewer cells than mexiletine did.

Variability in hiPSC-CMs observed *in vitro* is a known issue, widely demonstrated in the literature (see [Supplementary Table S2](#appsec1){ref-type="sec"}).[@bib1], [@bib2], [@bib5], [@bib14], [@bib15], [@bib16] A canonical *in silico* model, based on average data, can surely provide mechanistic insights on electrophysiological mechanisms; however, it is inadequate to capture and explain variability or its causes. Experimentally calibrated *in silico* populations provide a tool to explore a wide range of ionic scenarios, which enables recapitulation of the variability in experimental recordings and provides plausible explanations for the ionic mechanisms underlying variability in cardiac cell phenotypes. In our study, the control population provided a pool of models covering the experimental biomarker range (see [Supplementary Figure S3](#appsec1){ref-type="sec"}).[@bib1], [@bib2], [@bib5], [@bib14], [@bib15], [@bib16] Analysis shows interesting correlations between AP amplitude (APA) - peak potential (Peak) and V~Max~-MDP (the more negative the MDP, the larger the V~Max~ due to greater I~Na~ availability). This calibrated population of hiPSC-CM was "transfected" with the LQT3 mutation, and our results show agreement with the *in vitro* dataset reported by Ma et al.[@bib1] Of note, the mutant population was not obtained by direct experimental calibration, but the mutation was expressed in all the models of the experimentally calibrated control population. We chose this approach (as in Passini et al[@bib17]) for the following reasons: (1) this approach allowed an (almost) 1:1 correspondence between control and mutant models, while simultaneously allowing considering a wide range of ionic scenarios; and (2) there is only one experimental dataset for the LQT3 biomarkers[@bib1] rather than the six datasets available for control hiPSC-CMs. Calibrating the mutant population with 1 dataset only (containing 12 cells) would have dramatically limited the variability in the mutant population.

Our simulations suggest that strong repolarization reserve yields asymptomatic LQT3 models. Indeed, simulations showed that mutant models with normal APs (asymptomatic models) featured smaller inward I~CaL~ and stronger outward I~Kr~ and I~pCa~. Together with a smaller I~K1~, which affects the availability of Na^+^ currents, and the physiological variability of I~NaL~ conductance, such interplay of currents allows compensating for the LQT3 mutation in clinically asymptomatic mutant carriers. Results on the stronger I~pCa~ in particular require further evaluation, because such current usually is not as carefully characterized experimentally as other currents in cardiomyocyte models. We also studied the differences between the control models that became symptomatic after the introduction of the mutation and those that remained asymptomatic. The first group was characterized by a significantly longer AP (APD~90~ +34%). This shows that APs with specific characteristics, and weak repolarization reserve, may indicate symptomatic behavior in case of mutation.

Furthermore, our simulations are the first population-based *in silico* hiPSC-CM drug trial using control and mutant populations to assess in a wide range of ionic scenarios the effect of two drugs used in LQT3 treatments: mexiletine[@bib7] and ranolazine,[@bib10] Simulations confirmed the efficacy of mexiletine in shortening the APD in mutant cells, whereas they displayed slight APD~90~ prolongation in controls. These results are consistent with experiments by Malan et al.[@bib4] However, *in vitro* laboratory recordings are usually conducted on a limited number of cells (order of tens) because of the time and work required for cell culturing and wet lab experiments. As long as computing power and time are available for the simulations (see [Supplementary Table S11](#appsec1){ref-type="sec"}), *in silico* populations of models can be used to overcome these limitations and thus offer a powerful platform to further evaluate potential effects of mutations and drugs.

An additional finding is that mexiletine inhibited spontaneous APs in a large hiPSC-CM subgroup. At 20 μM, 784 of 1,401 models (56%) stopped producing APs. This behavior was due to a weak I~Na~ ([Figure 4D](#fig4){ref-type="fig"}, panels a and b), which could not trigger the upstroke despite I~Na~ activation due to strong I~K1~. Because we considered spontaneous APs, we tested low Na^+^ blocker concentrations, as stronger doses would have inhibited spontaneous APs. Furthermore, in a subgroup of mutant cells producing APs, APD~90~ was prolonged (23, 52, and 132 models at 5, 10, and 20 μM, respectively). Causes included delayed upstroke, due to a weak I~K1~ (impairing I~Na~ activation) ([Figure 4D](#fig4){ref-type="fig"}, panels c--f, and [Supplementary Figure S6](#appsec1){ref-type="sec"}) and a repolarization phase in which I~NaL~ was strongly reduced (median 44.9 vs 77.2 S/F, --42%), that is, it lacked part of the main mexiletine target, and I~CaL~ was increased (101 vs 84 cm^3^/F/s, +21%). Interestingly, the models presenting such prolongation at 20 μM were 91 of 132 (69%) asymptomatic and only 41 of 132 (31%) symptomatic phenotypes, suggesting unexpected mexiletine effects on asymptomatic cells. Although this behavior still requires experimental confirmation, we suggest that it should be considered when testing strong I~Na~ blockers on hiPSC-CMs, especially for spontaneous APs.

Finally, both ranolazine and mexiletine led to APD shortening to a comparable extent. Only a few mutant models (11, 23, and 83 at 5, 10, and 20 μM, respectively) showed APD prolongation, associated with low I~K1~ and I~NaL~ ([Figure 5D](#fig5){ref-type="fig"}, panels c--f). The lower occurrence of APD prolongation (58 of 83 symptomatic, 25 of 83 asymptomatic) for ranolazine than mexiletine was due to the smaller impact of ranolazine on I~Na~ (see [Supplementary Tables S3 and S6](#appsec1){ref-type="sec"}). This suggests that a key factor in the variability of the responses of LQT3 mutant cells to mexiletine and ranolazine is a fine balance between I~Na~, which is responsible for the upstroke phase, I~K1~, which strongly influences I~Na~ availability, and I~NaL~.

Importantly, both drugs were more effective on symptomatic than on asymptomatic hiPSC-CMs, showing greater APD~90~ shortening in the former and confirming their suitability as antiarrhythmic drugs, as confirmed by the simulations with the human adult models. At the same concentration (eg, 20 μM), ranolazine stopped spontaneous electrical activity or induced paradoxical prolongation in fewer hiPSC-CMs than mexiletine did.

Study limitations {#sec4.1}
-----------------

We acknowledge that more detailed modeling approaches to I~Na~, I~NaL~, and LQT3 are available (eg, Moreno et al[@bib19]), and those may be more suitable for detailed studies on arrhythmia mechanisms. In our study, we chose the simpler formulations based on a Hodgkin-Huxley model for the I~NaL~ mutation and a simple pore block model for current--drug interaction based on drug IC~50~ as these are often available for a variety of drugs and ionic currents. Furthermore, an assumption is that variability in ionic conductances is a major determinant of phenotypic variability. Our results demonstrate that this approach is sufficient to reproduce and investigate phenotypic variability in hiPSC-CMs in control and LQT3, and in response to two drugs. Other factors such as ionic current kinetics may make additional contributions (eg, in Britton et al[@bib13]), which could be explored in future studies. It also is possible that ionic backgrounds and phenotypes included in the populations are not observed in experiments and certainly in those used for calibration. This may be an advantage of the *in silico* population, as it allows investigation of a wider range of scenarios than experimentally, potentially highlighting possible phenotypes either not observed (eg, due to limited number of cells) or not reported (eg, termination of spontaneous activity interpreted as degradation of the preparation after drug administration).

Conclusion {#sec5}
==========

We demonstrated the ability of computer simulations to capture and offer hypotheses for variability in LQT3 and control hiPSC-CM phenotype and in their response to mexiletine and ranolazine. Populations of *in silico* hiPSC-CM models were constructed based on cellular and ionic recordings and were shown to be in agreement with available experimental data for control and LQT3 mutation, and after drug application. The mutant population was divided into symptomatic and asymptomatic models based on their AP characteristic. The symptomatic LQT3 hiPSC-CM models display weaker repolarization reserve compared to LQT3 hiPSC-CM with normal APD, primarily determined by I~NaL~, I~CaL~, I~Kr~, and I~K1~. Both mexiletine and ranolazine were shown to be generally effective in shortening APD of LQT3 hiPSC-CMs, with additional cell subgroups responding with both AP suppression and prolongation. Our results highlight the power of *in silico* populations of models in exploring phenotypic hiPSC-CM variability, thus supporting compound prescreening and aiding in the interpretation of *vitro* drug studies.

Appendix. Supplementary data {#appsec1}
============================
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